To Bailout ObamaCare or Not to Bailout?

 

When is a bailout not a bailout? That’s the big question facing Congress now.

In an earlier post I described the peculiar language that Congress uses to describe things so they are considered political correct, or incorrect, as it suits their agenda. (see The Misleading Language of Healthcare Reform) The latest word in this peculiar language is bailout.

Now that Democrats have successfully prevented Republicans from making the changes in ObamaCare they promised, it’s time to deal with an unpleasant issue. Cost-Sharing Reductions subsidies (CSRs) are payments by the government to the insurers to subsidize deductibles and co-pays for lower-income individuals – those below 250 percent of the Federal Poverty Level – who purchase coverage on ObamaCare’s exchanges.

Although these payments must be appropriated by Congress, the Obama administration made the payments without approval anyway. The result is a lawsuit called House of Representatives v. Price (the current HHS Secretary). This lawsuit was originally filed in 2015 against the Obama administration and a federal judge ruled in favor of the House. The judge initially slammed the Obama administration with an injunction to prevent further payments. However, the injunction was later stayed at Congress’ request, putting the legality and existence of CSRs in limbo.

President Trump had opposed what he calls “bailouts of insurance companies.” Insurers and Democrats are pressuring the White House to approve the payments to lower the cost of health insurance for low-income Americans.

Are these actually bailouts or not? Who is being bailed out?

Republicans call these bailouts of the insurance companies. Democrats call these necessary subsidies for low-income Americans. Insurers call these cost-sharing reductions.

Avik Roy, writing in Forbes, calls these payments “a bailout of ObamaCare’s sloppy authors.” He blames the authors for creating a healthcare system that is so overloaded with government regulations that it drives up the cost of insurance and makes these payments necessary.

The Congressional Budget Office (CBO) as usual has weighed into the fray with their opinion which Democrats routinely pounce on to justify their position. The CBO predicts 20% premium increases in 2018 if the Trump administration fails to make the CSR payments. They also say the higher subsidies mean that the increased spending on tax cuts will add $194 billion to the deficit through 2026, according to The Wall Street Journal. Ending the subsidies would add $6 billion to the deficit next year.

However, there is some good news. The CBO says that failure to make the payments would produce no significant change in the number of insured individuals, at least not any time soon. Analyst Charles Blahous says the report shows that killing the subsidies could lower costs for some consumers, especially the near-elderly, whose premiums would rise very little while they would be able to afford gold plans that are worth more.

Roy says the prudent thing to do is to pass a short-term, one-year funding package for ObamaCare’s CSRs, in exchange for real reforms of the individual insurance market.

 

Real Reforms

The suggested real reforms include the following:

  • Repeal of the Individual Mandate – to give people freedom not to purchase insurance. A six-month waiting period to re-enroll would help lower premiums by incentivizing people to remain enrolled.
  • Eliminating the “age bands” – that force insurers to overcharge younger enrollees. The young would pay less, enroll more, and therefore drive down premiums for everyone.

 

Conservatives would rather not put any more taxpayer funds into the healthcare system but a short-term funding package with these reforms could lead to long-term lower premiums.

Medicaid and The Killer Drugs

 

Medicaid causes many problems, not to mention it provides second-class healthcare. In recent posts I have pointed to the negative impact of Medicaid on state budgets and education (Medicaid – The State Killer) and its negative impact on the defense of our nation (Medicaid – The Defense Killer.) Today we’ll talk about how Medicaid is contributing to the epidemic of opioid abuse that is killing people.

President Trump declared recently the opioid epidemic is a national emergency. The proof of this is irrefutable. According to The Wall Street Journal, drugs now rank as the leading cause of death for Americans under age 50. Think about that. That’s higher than auto accidents, higher than cancer, higher than diabetes or heart disease. It’s even higher than urban violence that is booming in big cities like St. Louis, Chicago, Detroit, and Baltimore.

Opioid overdoses have quadrupled since 1999, and fatalities are soaring. The number of overdoses in Ohio alone this year is projected to exceed the nationwide count in 1990. In the mostly rural state of New Hampshire, opioid abuse was a major issue in the 2016 presidential campaign.

Most opioid abuse and overdoses begin with prescription painkillers that lead to addiction. Although the majority of people prescribed these drugs never become addicted, a significant minority get hooked and then turn to street drugs to feed their addiction. These street drugs are usually laced with fentanyl and heroin, far stronger opioids with lethal side effects.

How does Medicaid impact this picture?

A recent study by Express Scripts Holding found that about a quarter of Medicaid patients were prescribed an opioid in 2015. Wisconsin Senator Ron Johnson has called attention to evidence that the Medicaid expansion under ObamaCare may be contributing to the rise in opioid abuse.

According to a federal Health and Human Services (HHS) analysis requested by Senator Johnson, overdose deaths per million residents rose twice as fast in the 29 Medicaid expansion states – those that increased eligibility to 138% from 100% of the federal poverty level (FPL), than in the 21 non-expansion states between 2013 and 2015.

It is especially alarming to note the marked disparities between neighboring states based on whether they opted into ObamaCare’s Medicaid expansion. Deaths increased twice as much in New Hampshire (108%) and Maryland (44%) – where Medicaid expanded – as in Maine (55%) and Virginia (22%). Drug fatalities skyrocketed by 41% in expansion Ohio while climbing only 3% in non-expansion Wisconsin.

Vast quantities of opioids can be obtained cheaply with Medicaid cards. A police detective in Wisconsin told Senator Johnson’s office that 240 oxycodone pills can be purchased with a Medicaid card for a $1 co-pay and resold for $4,000 on the street! A single Vicodin pill (hydrocodone) sells for as much as $50.

Senator Johnson says, “It appears that the program has created a perverse incentive for people to use opioids, sell them for large profits and stay hooked.” He is calling for the Inspector General of HHS to investigate Medicaid’s controls to prevent such abuses. Hopefully, President Trump’s emergency declaration will provide funding for expanded opioid treatment. But it is clear that reigning in the abuse of Medicaid is an important part of the solution.

Lowering Drug Prices

 

The high price of drugs is an issue that politicians flock to like moths to a flame. It makes them feel important as they register their outrage and their determination to do something about it.

But interfering with the free market forces that control our economy is fraught with disaster. Price controls and other government interference in the market usually leads to unintended consequences – like shortages, fewer jobs, or both.

Case in point is what is happening in state legislatures in a vain attempt to control drug prices. The Wall Street Journal editorial board calls attention to the states of Nevada and Maryland where lawmakers are passing bills to punish drug companies without benefitting patients.

Nevada Republican Governor Brian Sandoval vetoed a bill on diabetes medication. The bill passed easily through the legislature and may make a comeback. Here’s what the bill proposed according to the WSJ:

            “The state would have decided what counts as an “essential” diabetes medicine, including insulin and others. Manufacturers would be required to disclose the cost of production and marketing, as well as profits and more. That information is proprietary and hard to calculate, as the cost of medicines is influenced by research and development over many years.”

            “Manufacturers would have to inform the state 90 days in advance of any price increase, which is nothing but a heads up to the folks running the public shaming campaign. Some purchasers would stockpile meds before the price ticks up, which could lead to shortages. The bill requires new disclosures for pharmaceutical representatives, and industry already regulated by the Food and Drug Administration.”

 

In other words, politicians want to tell these drug companies to reveal their trade secrets and their financial status so the government can tell them how much they are allowed to charge and how much profit they are allowed to make. If allowed to happen, this kind of government interference is likely to lead to fewer manufacturers – which will lead to higher prices!

Competition always leads to lower prices! This tried and true Economics 101 fact is displayed in the following graphic:

An FDA analysis in 2005 revealed that patients pay 94% of the branded price when a medicine has one generic competitor. That falls to about 20% of the price when eight companies are competing for market share. The graphic clearly shows the more companies producing the drug, the lower the price.

The solution to high drug prices is therefore, more manufacturers, not fewer. But the politicians attack the manufacturers, making competition less likely. The state of Maryland recently gave the Attorney General the authority to investigate any generic drugmaker responsible for an “unconscionable” price increase. The WSJ says “the left defines unconscionable as paying money for any health-care product or service.”

They say that generic drugs fill nearly 90% of all prescriptions but account for only 27% of total drug costs. State and federal programs are among the largest purchasers of generic drugs, and in 2015 generics saved more than $32 billion in Medicaid alone. Generic drugs saved Maryland $3.7 billion in 2015.

Increasing the number of generic drug manufacturers has been a problem under previous administrations. That looks to change under new FDA Commissioner Scott Gottlieb who is on a mission to increase the number of companies making generic drugs. Gottlieb is preparing a plan to drive more generic innovation and competition, including streamlining the approval process. Such changes will lower drug prices for everyone, unlike the politicians who try to impose their own solutions.